Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00336986 | Efficacy Study of IL-21 to Treat Metastatic Melanoma | completed | Phase 2 | 54 | Novo Nordisk A/SINDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT00053781 | Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma | completed | Phase 2 | 18 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00514085 |
| Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma |
| completed |
| Phase 2 |
| 40 |
| NCIC Clinical Trials GroupNETWORK |
| 1 |
| Aug 4, 2023 |
| clinicaltrials |
| NCT03416933 | Therapeutic Drug Monitoring of BRAF-mutated Advanced Melanoma(OPTIMEL) | completed | N/A | 35 | Institut de Cancérologie de LorraineOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05740501 | Pharmacokinetic Profiling of Pembrolizumab and Nivolumab in Patients With Melanoma and/or Non-Small Cell Lung Cancer | completed | — | 13 | Mayo ClinicOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
| NCT03581188 | Patient-led Surveillance Compared to Clinician-led Surveillance in People Treated for Localised Melanoma.(MEL-SELF) | completed | N/A | 100 | University of SydneyOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT00591370 | Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 25, 2023 | clinicaltrials |
| NCT04576416 | Artificial Intelligence Augmented Training in Skin Cancer Diagnostics for General Practitioners(AISC-GP) | completed | N/A | 115 | Herlev HospitalOTHER | 1 | Jul 25, 2023 | clinicaltrials |
| NCT05661370 | App Teaches Doctors to Diagnose Skin Cancer | completed | N/A | 3 | Herlev HospitalOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT03679767 | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | completed | Phase 2 | 121 | Incyte CorporationINDUSTRY | 8 | Jul 21, 2023 | clinicaltrials |
| NCT01176474 | Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma | completed | Phase 1 | 73 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT04452214 | A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors | completed | Phase 1 | 19 | Cantargia ABINDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT00700882 | Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 81 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 3, 2023 | clinicaltrials |
| NCT00049530 | PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma | completed | Phase 2 | 32 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00071981 | Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 175 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 28, 2023 | clinicaltrials |
| NCT01955941 | Vascular Response to Brachytherapy Using Functional OCT | completed | — | 49 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT00003027 | Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma | completed | Phase 3 | 482 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00003308 | Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 4 | Jun 22, 2023 | clinicaltrials |
| NCT00003444 | Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin | completed | Phase 3 | 167 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00001503 | Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease | completed | — | 1,031 | National Cancer Institute (NCI)NIH | 1 | Jun 18, 2023 | clinicaltrials |
| NCT00003601 | Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome | completed | Phase 2 | 38 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 18, 2023 | clinicaltrials |
| NCT01288963 | IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma | completed | — | 153 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02575404 | GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients | completed | Phase 1 | 36 | Providence Health & ServicesOTHER | 1 | Jun 5, 2023 | clinicaltrials |
| NCT03973151 | Study of HL-085 in NRAS Mutant Advanced Melanoma | completed | Phase 1 / Phase 2 | 42 | Shanghai Kechow Pharma, Inc.INDUSTRY | 1 | May 31, 2023 | clinicaltrials |
| NCT05217303 | HL-085 in NRAS-mutated Advanced Melanoma | completed | Phase 2 | 100 | Shanghai Kechow Pharma, Inc.INDUSTRY | 1 | May 31, 2023 | clinicaltrials |
| NCT01658917 | Collecting Solid Tumor Tissue to Identify New Treatments | completed | — | 133 | National Cancer Institute (NCI)NIH | 1 | May 30, 2023 | clinicaltrials |
| NCT04547946 | Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib) | completed | — | 3 | Novartis PharmaceuticalsINDUSTRY | 1 | May 30, 2023 | clinicaltrials |
| NCT05874817 | Retrospective Assessment of AE-Related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma | completed | — | 17,517 | Novartis PharmaceuticalsINDUSTRY | 1 | May 25, 2023 | clinicaltrials |
| NCT01543113 | cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project(KitMel) | completed | N/A | 288 | Rennes University HospitalOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT02470273 | Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID) | completed | — | 143 | Rockefeller UniversityOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT01502293 | Trial of pIL-12 Electroporation Malignant Melanoma(IL-12MEL) | completed | Phase 2 | 51 | OncoSec Medical IncorporatedINDUSTRY | 1 | May 15, 2023 | clinicaltrials |
| NCT00790010 | Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma | completed | Phase 1 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT03171064 | Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment(Sportivumab) | completed | Phase 2 | 39 | University Hospital HeidelbergOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT00504582 | Fibrin Melanoma Axillary Node Study in Patients With Melanoma | completed | N/A | 121 | M.D. Anderson Cancer CenterOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05389085 | Fast Track Diagnosis of Skin Cancer by Advanced Imaging Technologies and Tumour Tapestripping | completed | N/A | 75 | University Hospital Bispebjerg and FrederiksbergOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT03408587 | CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)(CLEVER) | completed | Phase 1 | 11 | ViralyticsINDUSTRY | 1 | May 6, 2023 | clinicaltrials |
| NCT02141542 | Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma | completed | Phase 1 | 15 | F. Stephen Hodi, MDOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | Fate TherapeuticsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT04570722 | Ipsilateral Peripheral Intravenous Access Procedures (The iPIVAP Study)(iPIVAP) | completed | N/A | 3 | Duke UniversityOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT01191775 | A Study of PNT2258 in Patients With Advanced Solid Tumors | completed | Phase 1 | 22 | Sierra Oncology LLC - a GSK companyINDUSTRY | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05817149 | Perioperative Examination of Inflammatory Markers in Relation to Sentinel Lymph Node Biopsy in Patients With Melanoma; a Pilot Study | completed | — | 20 | Aalborg University HospitalOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT01359956 | Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma(SICOG 0109) | completed | Phase 3 | 269 | National Cancer Institute, NaplesOTHER | 0 | Apr 11, 2023 | clinicaltrials |
| NCT01164891 | A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma | completed | Phase 1 | 7 | Hoffmann-La RocheINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT02120222 | Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery(KPT-330) | completed | Phase 1 | 8 | Kari KendraOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT04435964 | Gender Difference in sidE eFfects of ImmuNotherapy: a Possible Clue to Optimize cancEr tReatment(G-DEFINER) | completed | — | 247 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT02570308 | A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma | completed | Phase 1 / Phase 2 | 146 | Immunocore LtdINDUSTRY | 5 | Mar 21, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Aug 14, 2023source: clinicaltrials